GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Dame Emma Walmsley is the Chief Executive Officer of GSK plc, joining the firm since 2011.
What is the price performance of GSK plc stock?
The current price of GSK plc is $27.11, it has decreased 0% in the last trading day.
What are the primary business themes or industries for GSK plc?
GSK plc belongs to Pharmaceuticals industry and the sector is Health Care
What is GSK plc market cap?
GSK plc's current market cap is $108.4B
Is GSK plc a buy, sell, or hold?
According to wall street analysts, 26 analysts have made analyst ratings for GSK plc, including 5 strong buy, 7 buy, 15 hold, 4 sell, and 5 strong sell